Return to Growth for Pharmaceutical Sector: Surge in Drug Approvals, R&D Productivity and Investor Confidence to Drive Expansion Through 2018

London And Boston (ots/PRNewswire) -

The industry is poised for a healthier turn after sales declined
in 2012,

says Evaluate's "World Preview 2013, Outlook to 2018" report

According to the newly-released World Preview report from market
intelligence firm Evaluate Ltd, the worst of the patent cliff is
behind us. While the pharmaceutical industry is feeling the effects
of last year's decline in performance - with worldwide prescription
drug sales down 1.6%- sales are forecast to start growing slowly in
2013 and then steadily increase, reaching $895 billion by 2018,
according to Evaluate's report, "World Preview 2013, Outlook to 2018:
Returning to Growth [http://www.evaluategroup.com/wp2013 ]."

The sixth-edition World Preview report examines life after the
patent cliff, providing top-level insight from the world's financial
markets into the expected performance of the industry between now and
2018. The report was released today at the 2013 Drug Information
Association (DIA) Annual Meeting in Boston, USA, and is available as
a free download at http://www.evaluategroup.com/wp2013.

According to the World Preview 2013, the industry will benefit
from improved investor confidence and R&D productivity. Of the $227bn
of global drug sales that will be at risk from generic erosion
following patent expirations, only $110bn is forecast to be lost over
the next five years. The main reason for this is the growing
contribution of biological products to global sales. By 2018, 50% of
sales of the top 100 products are predicted to come from biological
products which are expected to experience less sales erosion from
biosimilar competition than traditional small molecules have from
generic products.

"The fall in worldwide prescription drug sales in 2012 confirms
our forecast from last year," said Anthony Raeside, Head of Research
for Evaluate. "While patent expirations still threaten to stifle
growth, the market is expected to grow sluggishly in 2013 with a
sustained recovery occurring in 2014."

In addition to assessing trends in prescription drug sales, the
World Preview 2013 report also examines key topics including R&D
spending, therapy category growth, the performance of marketed and
pipeline products, and overall 2012 performance. Among this year's
key findings:

- Pfizer reigned as the top pharmaceutical company in terms of worldwide
prescription drug sales in 2012, with Novartis directly behind. By 2018, Novartis will
take over as the biggest pharmaceutical company for worldwide prescription drug sales.
- Worldwide pharmaceutical R&D spend is forecast at $149bn in 2018 growing at an
average annual rate of 1.4% between 2012 and 2018.
- Teva Pharmaceuticals remained the leading generic drug maker in 2012.
- The anti-coagulant market will grow 11.5% between 2012 and 2018, achieving the
highest worldwide sales growth of major therapy categories. Meanwhile, within the top
100 prescription products, biological products are expected to account for more than
50% of sales in 2018.
- Orphan drugs [http://www.evaluategroup.com/orphandrug2013 ] are expected to
account for $127bn of sales in 2018, representing 16% of the entire worldwide
prescription market.
- AbbeVie's Humira is forecast to be the world's biggest selling product in
2018.
- Gilead's hepatitis C polymerase inhibitor, Sofosbuvir, remains the most
valuable R&D product.

For more information on the 2013 Edition of the World Preview
report, visit Evaluate booth #630 at the DIA meeting. The executive
summary and full report are available for download at
http://www.evaluategroup.com/wp2013.

About Evaluate Ltd.

Established in 1996, Evaluate Ltd. is the leader in high quality
life science sector analysis. EvaluatePharma
[http://www.evaluategroup.com/EvaluatePharma-Overview.aspx ] delivers
exclusive consensus forecasts and trusted commercial insight into
biotech and pharmaceutical performance. EvaluateMedTech
[http://www.evaluategroup.com/public/EvaluateMedTech-Overview.aspx ]
sets a new standard in integrated analysis and consensus forecasts of
the global medical device and diagnostic industry.
EvaluateClinicalTrials [http://www.evaluategroup.com/public/Evaluate
ClinicalTrials-Overview.aspx ] delivers unique intelligence to
efficiently and accurately analyze the global clinical trial
landscape. A team of more than 85 dedicated healthcare analysts
employ rigorous methodologies to collate, organize and deliver the
most-up-to-date commercial performance data available. An
award-winning editorial team of journalists writing under the EP
Vantage name support EvaluatePharma's analysis. The Evaluate services
enable the life science community to make sound business decisions
about value and opportunity. For more information please visit
http://www.evaluategroup.com. On Twitter: @evaluatepharma
[https://twitter.com/evaluatepharma ], @evaluatemedtech
[https://twitter.com/EvaluateMedTech ], @epclinicaltrial
[https://twitter.com/EPClinicalTrial ], @epvantage
[https://twitter.com/EPVantage ].

Media Contacts:
Evaluate and EP Vantage
Christine Lindgren
+1-617-866-3906
christine.lindgren@evaluategroup.com

Chempetitive Group (for US media)
Rachel Lear
Kelly Quigley
+781-775-3640
+1-858-997-9462
rlear@chempetitive.com
kquigley@chempetitive.com

College Hill (for non-US media)
Melanie Toyne Sewell
Stefanie Bacher
Gemma Howe
+44-(0)20-7457-2020
evaluate@collegehill.com

ots Originaltext: Evaluate Ltd.
Im Internet recherchierbar: http://www.presseportal.de